Long-term effects of a combination of isoflavones, agnus castus and magnolia extracts on climacteric symptoms and cardiometabolic risk profile in postmenopausal women. (3rd April 2022)

• Record Type: Journal Article
• Authors: Maffei, Silvia; Franchini, Michela; Fortunato, Loredana; Guiducci, Letizia
• Is Part Of: Gynecological endocrinology. Volume 38:Number 4(2022)
• Page Start: 339
• Page End: 344
• Publication Date: 2022-04-03
• Subjects: Climacteric syndrome -- postmenopausal women -- cardiometabolic risk -- isoflavones -- Agnus castus -- magnolia; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2022.2047171
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Objective: To evaluate the long-term effects of a combination of isoflavones, agnus castus and magnolia extracts (combined isoflavone compound [CIC]) on climacteric symptoms and cardiometabolic risk in symptomatic postmenopausal women. Methods: This interventional, prospective study evaluated climacteric symptoms, mood and sleep disorders using the 21-item Greene Climacteric Scale (GCS) and 7-item Insomnia Severity Index (ISI) questionnaires; and cardiovascular, metabolic and thrombotic risk markers at baseline (T0) and after 12 months of CIC treatment (T1). Results: In healthy postmenopausal women ( N = 71), 12-month CIC treatment significantly reduced patient-reported vasomotor symptoms (100% vs. 17%), mood disorders (67% vs . 25%) and sleep disorders (89% vs. 19%%) (all p < .001) compared with baseline; and significantly improved GCS psychological, somatic, and vasomotor domain scores and ISI sleep disturbance scores (all p < .05). CIC significantly reduced systolic ( p = .022) and diastolic blood pressure ( p < .001), and heart rate ( p < .001); glucose concentrations ( p = .018), HOMA index ( p = .013), and ALT ( p = .035), homocysteine ( p = .005) and NT-proBNP ( p = .003) levels. Conclusions: Long-term CIC therapy improved vasomotor symptoms, mood disorders, sleep disorders, hemodynamic measurements and cardiometabolic risk markers in healthy postmenopausal women. ClinicalTrials.gov Identifier: NCT03699150.